AI-generated summary
The authors randomised 60 patients with Hashimoto's thyroiditis to active or sham photobiomodulation therapy twice weekly for three weeks, alongside levothyroxine. They report that fatigue, sleep quality, daytime sleepiness and behavioural status improved in both groups, with greater improvement in the active group. The authors concluded that the therapy reduced clinical symptoms in these patients.
- Participants
- 60
- Who or what was studied
- Patients with Hashimoto's thyroiditis who continued levothyroxine replacement therapy
- Limits stated in the abstract
- The abstract does not report the wavelength, dose or follow-up beyond three months, and does not state how the authors addressed the risk of bias in outcome assessment.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
The standard lifelong treatment for Hashimoto’s thyroiditis (HT), a chronic autoimmune disease, is levothyroxine (LT4) therapy. Despite LT4 replacement therapy, patients continue to experience persistent fatigue, deterioration in psychological and general well-being. Our study was conducted to investigate the effects of photobiomodulation therapy (PMBT) combined with LT4 replacement therapy on fatigue and behavioural status in patients with HT.
Methods
Sixty patients with HT were randomised to receive active or sham PMBT twice weekly for three weeks. Clinical evaluations of the participants were performed before and at the third months after treatment. Fatigue was assessed using the Fatigue Impact and Severity Scale, sleep quality and sleepiness using the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale, and behavioural status using the Beck Anxiety and Depression Inventory.
Results
At the end of the treatment fatigue severity, sleep quality, daytime sleepiness and behavioural status were improved in both groups. In the between-group comparisons, all clinical symptom states showed a significant improvement in favour of the active group (p < 0.05).
Conclusions
As a result, we concluded that PMBT is an effective method to reduce clinical symptoms in patients with HT.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Depression, Anxiety, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.